Brooklyn ImmunoTherapeutics, Inc.(NYSE Amex Equities : BTX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.93%||169.77||0.7%||$1345.09m|
|MRK||Merck & Co., Inc.||0.64%||78.50||0.7%||$923.31m|
|BMY||Bristol-Myers Squibb Co.||0.91%||65.12||1.0%||$723.23m|
|LLY||Eli Lilly & Co.||1.39%||195.02||1.1%||$577.79m|
|BTX||Brooklyn ImmunoTherapeutics, Inc.||4.90%||28.73||12.8%||$330.24m|
|NVO||Novo Nordisk A/S||0.73%||78.61||0.1%||$70.62m|
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.